Johannes Stadlmann

Johannes Stadlmann is an Assistant Professor at the Institute of Biochemistry (DCH/BC) within the Department of Chemistry at the University of Natural Resources and Life Sciences (BOKU) in Vienna since 2020. His academic journey includes positions as a Staff Scientist at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) from 2015-2020, Post-Doctoral Fellow at the Institute for Molecular Pathology (IMP) from 2010-2013, and earlier postdoctoral work at BOKU from 2009-2010. He earned his Doctorate (Dr. nat. techn.) from BOKU between 2004-2009.

Dr. Stadlmann's primary research focuses on glycobiology with particular emphasis on N-glycans and O-glycans. His work spans multiple disciplines including biochemistry, molecular biology, and analytical chemistry. He has made significant contributions to understanding glycan structures in various biological contexts, including viral infections, bacterial interactions, and mammalian tissue diversity. His research employs advanced techniques such as mass spectrometry, NMR spectroscopy, and glycoproteomics to analyze complex carbohydrate structures and their biological functions.

Analysis of his recent publications reveals a strong trend toward comprehensive glycome profiling across different biological systems. His work demonstrates increasing sophistication in analyzing isomer-sensitive N-glycome patterns, with applications ranging from understanding organ-specific diversity in mammalian systems to developing therapeutic approaches for viral infections. A notable theme in his research is the application of glycan analysis to solve practical problems in medicine and biotechnology, including coronavirus research, periodontal health, and neurodevelopmental disorders.

Dr. Stadlmann has supervised multiple academic theses, including Helm J.'s 2023 dissertation on "Analysis of isomeric N-glycans with PGC-ESI-MS" and Gamperl A.'s 2022 master's thesis on "Enzyme activity determination of carbohydrate methylases." He has been involved in significant research projects including "Recombinant Pharmaceuticals from Plants for Human Medicine" (2004-2009), demonstrating his long-standing interest in applying biochemical principles to pharmaceutical development. His work has resulted in over 100 publications spanning diverse areas of glycobiology and its applications.